Variant-Specific IgA Protects Against Omicron Infection.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37996071.
- Also identified by DOI 10.1093/infdis/jiad525 and PMC identifier 11326848.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The emergence of rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, coupled with waning vaccine-induced immunity, has contributed to the rise of vaccine breakthrough infections. It is crucial to understand how vaccine-induced protection is mediated. We examined 2 prospective cohorts of mRNA vaccinated and boosted individuals during the Omicron wave of infection in Singapore. We found that individuals who remain uninfected over the follow-up period had a higher variant-specific IgA, but not IgG, antibody response at 1 month after booster vaccination, compared with individuals who became infected. We conclude that IgA may have a potential contributory role in protection against Omicron infection. Clinical Trials Registration . NCT05142319.
Medical subject headings
- Antibodies, Viral
- COVID-19
- COVID-19 Vaccines
- Immunoglobulin A
- SARS-CoV-2